<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Pharmaceutical Sciences</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D527967C-F2CF-4E39-928E-B7A6E847C7B1"><gtr:id>D527967C-F2CF-4E39-928E-B7A6E847C7B1</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Bevan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500847"><gtr:id>02DF0DEA-ABA9-4DCC-90EE-64EB6E28EAB2</gtr:id><gtr:title>Sensory transduction mechanisms in chronic pain</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500847</gtr:grantReference><gtr:abstractText>Pain normally protects us from damaging ourselves or warns us of an injury so that we protect the injured part of the body. In these cases, the pain ceases when the harmful stimulus has gone or the injury has healed. However, in some people the pain is persistent, is no longer associated with injury and has no beneficial protective effect. This chronic pain is associated with some cancers and inflammatory diseases such as arthritis, and can occur after viral infection of the nerves that normally sense pain or after nerve damage associated with diabetes. It is estimated that 300 million people in the world suffer from chronic pain. The current pain killing drugs are mostly based on aspirin or are opiates. The aspirin-like drugs have the drawbacks that they can cause stomach bleeding and are ineffective against nerve injury pain. Apart from concerns about addiction, the opiate like drugs cause sedation, severe constipation and may even stop the patient breathing. The only other types of drugs used to treat nerve injury pain ? anticonvulsant drugs ? also have pronounced undesirable side effects, such as severe dizziness. So there is a large need for new pain killing drugs.</gtr:abstractText><gtr:technicalSummary>The molecules responsible for cold and mechanical transduction in sensory neurons in normal and chronic pain conditions are poorly understood. Molecules of the transient receptor potential (TRP) channel family are strong candidates as tranducers for these modalities. We will examine the roles of candidate TRP channels in mechano- and cold-transduction in normal and chronic pain conditions. Candidate TRP channels will be expressed in heterologous mammalian cells and their physiological and pharmacological properties determined. These properties will be compared with those of native channels in isolated sensory neurons. We will also investigate the role of individual TRP channels by molecular ?knock down? with antisense oligonucleotides (ASO) or small interfering RNA (siRNA) both in vitro and in vivo. A key part of our studies will be an examination of the behavioural effects of interfering with the actions of specific TRP channels with ASO/siRNA on mechano- and cold-transduction in normal and pathophysiological conditions. In this way we will determine:
A. What ion channels mediate innocuous and noxious mechanical transduction in sensory nerves. B. What contributions the identified ion channels make to mechanical hyperalgesia and allodynia in chronic pain conditions in vivo. C. What ion channels are responsible for innocuous and noxious cold transduction and how these channels contribute to cold allodynia in chronic pain. D. How the properties of mechano-and cold-sensitive channels are regulated in chronic pain states and the possible identity of any endogenous activators.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-03-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>531746</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Division of Clinical Chemistry and Pharmacology</gtr:department><gtr:description>Lund University</gtr:description><gtr:id>4D4FDF5F-F011-4099-ABF1-2803AD298E9E</gtr:id><gtr:impact>One published manuscript (18031925) and another manuscript submitted for publication.
Multidisciplinary: Biology, Chemistry</gtr:impact><gtr:outcomeId>QRN1P3V6Rk7-1</gtr:outcomeId><gtr:partnerContribution>The collaboration has extended our studies on TRP channels in new directions. Expertise in bladder physiology by collaborators led to a publication, while their expertise in clinical chemistry has resulted in new areas of collaborative research on the mechanism of action of an analgesic drug. The collaborator synthesized compounds that were not available from commercial sources.</gtr:partnerContribution><gtr:piContribution>My research team contributed expertise on ion channel physiology, assay technology and in vivo behavioural readouts for pain and analgesia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Lund University</gtr:description><gtr:id>98705116-971A-41D7-BF78-6347D49D6B26</gtr:id><gtr:impact>One published manuscript (18031925) and another manuscript submitted for publication.
Multidisciplinary: Biology, Chemistry</gtr:impact><gtr:outcomeId>QRN1P3V6Rk7-2</gtr:outcomeId><gtr:partnerContribution>The collaboration has extended our studies on TRP channels in new directions. Expertise in bladder physiology by collaborators led to a publication, while their expertise in clinical chemistry has resulted in new areas of collaborative research on the mechanism of action of an analgesic drug. The collaborator synthesized compounds that were not available from commercial sources.</gtr:partnerContribution><gtr:piContribution>My research team contributed expertise on ion channel physiology, assay technology and in vivo behavioural readouts for pain and analgesia</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>597327</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L010747/1</gtr:fundingRef><gtr:id>237DD068-7858-4D34-B453-B0EB0176AB77</gtr:id><gtr:outcomeId>56ddc9eb62d9b3.97435221</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>322021</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (The roles of TRPM8 in mechanotransduction and osmosensation)</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT092648</gtr:fundingRef><gtr:id>C1678D8D-4298-496D-A389-B908F115194B</gtr:id><gtr:outcomeId>Hb7dS9XNP1B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>227EBB80-F6A5-412D-8FC6-DC2B53AA957A</gtr:id><gtr:title>Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9f8ba84a5b1488c2a1fd4ebee25111a"><gtr:id>e9f8ba84a5b1488c2a1fd4ebee25111a</gtr:id><gtr:otherNames>Andersson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>2C4A95AF658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E289311-2C87-4AD1-89C1-659489889DF6</gtr:id><gtr:title>Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2484c18bca6fd0945e72c09f4dad0abd"><gtr:id>2484c18bca6fd0945e72c09f4dad0abd</gtr:id><gtr:otherNames>Streng T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>C95701E38E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67C20345-CCE4-4D19-9948-24285D0BA397</gtr:id><gtr:title>Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9f8ba84a5b1488c2a1fd4ebee25111a"><gtr:id>e9f8ba84a5b1488c2a1fd4ebee25111a</gtr:id><gtr:otherNames>Andersson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>7816AF4FABD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2210C59D-A54B-46E2-8410-6E1E0C0DC35B</gtr:id><gtr:title>The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/984ceade14660c83fd62d64674102a49"><gtr:id>984ceade14660c83fd62d64674102a49</gtr:id><gtr:otherNames>Gentry C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>B1217CA9DB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AF75394-3C4A-4270-A4B7-B217CBE3F6F1</gtr:id><gtr:title>TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid ?(9)-tetrahydrocannabiorcol.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9f8ba84a5b1488c2a1fd4ebee25111a"><gtr:id>e9f8ba84a5b1488c2a1fd4ebee25111a</gtr:id><gtr:otherNames>Andersson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>CXkQyqw9CuZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01E69ECA-8532-40BF-88FF-4E52960FD465</gtr:id><gtr:title>Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/295600a7855ef21bed2f790ae2d1cbb3"><gtr:id>295600a7855ef21bed2f790ae2d1cbb3</gtr:id><gtr:otherNames>Pozsgai G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_15173_23_20442136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD6B282F-2019-41F6-AC52-72682B3619AC</gtr:id><gtr:title>Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9f8ba84a5b1488c2a1fd4ebee25111a"><gtr:id>e9f8ba84a5b1488c2a1fd4ebee25111a</gtr:id><gtr:otherNames>Andersson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>DDFF87BB7E6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4813C33F-1C9D-4278-B6E6-348F5317F754</gtr:id><gtr:title>Methylglyoxal evokes pain by stimulating TRPA1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9f8ba84a5b1488c2a1fd4ebee25111a"><gtr:id>e9f8ba84a5b1488c2a1fd4ebee25111a</gtr:id><gtr:otherNames>Andersson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e141e141a63f86</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F9B2789-3911-4C5C-B796-486AE32CAAD5</gtr:id><gtr:title>Role of the cysteine protease cathepsin S in neuropathic hyperalgesia.</gtr:title><gtr:parentPublicationTitle>Pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebecaf23bc3cf506fedd22eaf2569f65"><gtr:id>ebecaf23bc3cf506fedd22eaf2569f65</gtr:id><gtr:otherNames>Barclay J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0304-3959</gtr:issn><gtr:outcomeId>88CA6C195BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9425C395-E096-4836-9DD3-566FE32D03D8</gtr:id><gtr:title>Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1fd850989ded61287c6584afcec3265"><gtr:id>b1fd850989ded61287c6584afcec3265</gtr:id><gtr:otherNames>Clark AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>997A1979095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75534D65-6166-4408-9374-9D7669700D84</gtr:id><gtr:title>TRP channel antagonists for pain--opportunities beyond TRPV1.</gtr:title><gtr:parentPublicationTitle>Current opinion in investigational drugs (London, England : 2000)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f33b916abdc898111dd259da63abf29"><gtr:id>1f33b916abdc898111dd259da63abf29</gtr:id><gtr:otherNames>Bevan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-4472</gtr:issn><gtr:outcomeId>DE72C272E99</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500847</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>